Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Denmark

Aarhus University Hospital, Aarhus

Phase

Early testing / Safety & dosing

Sponsor

University of Aarhus

Collaborators

The Peter Doherty Institute for Infection and Immunity, Walter and Eliza Hall Institute of Medical Research

Enrollment target

~18 participants

Started

April 2024

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated April 2025